{"meshTags":["Antibodies, Monoclonal","Humans","Male","Female","Quinazolines","Erlotinib Hydrochloride","Proto-Oncogene Proteins c-met","Carcinoma, Non-Small-Cell Lung","Antineoplastic Combined Chemotherapy Protocols"],"meshMinor":["Antibodies, Monoclonal","Humans","Male","Female","Quinazolines","Erlotinib Hydrochloride","Proto-Oncogene Proteins c-met","Carcinoma, Non-Small-Cell Lung","Antineoplastic Combined Chemotherapy Protocols"],"publicationTypes":["Comment","Journal Article","Research Support, Non-U.S. Gov\u0027t"],"abstract":"Rapid development of molecularly targeted drugs requires a \"companion diagnostic\" that could delay drug development and limit availability of active drugs for relevant patients. Were the negative results from MetMab studies in patients with advanced non-small cell lung cancer due to drug failure or failure of the right companion diagnostic?","title":"\"Companion diagnostics\": has their time come and gone?","pubmedId":"25059519"}